Overall, our analyses confirmed the central targets across multiple cancers such as the growth factor receptors (e.g., EGFR), while also revealing new viable targets such as the nuclear hormone receptor (e.g., ESR1) pathways in lung cancers, and supported the application of new single and combinatorial targeted approaches for the treatment of specific cancers. Here, ESR1 is linked to lung cancer.